# Fetal and Neonatal Immune Response to Congenital Cytomegalovirus (cCMV) Infection: A Systematically Conducted Scoping Review

**Authors:** Chrysanthi-Eleni Loizou, Antonios Gkantaras, Sofia Karagiannidou, Garyfallia Syridou, Despoina Gkentzi, Vassiliki Papaevangelou, Evangelia Farmaki

PMC · DOI: 10.3390/v18020242 · Viruses · 2026-02-14

## TL;DR

This review summarizes how fetuses and newborns respond to cCMV infection, highlighting immune patterns and their potential impact on long-term health.

## Contribution

The study provides a comprehensive overview of immune responses to cCMV, identifying key immune markers and gaps in understanding.

## Key findings

- cCMV-infected fetuses show strong γδ and CD8+ T-cell responses from the second trimester.
- Neonates exhibit functional NK and CD8+ T-cell responses but impaired CD4+ T-cell responses.
- A 16-gene biosignature is linked to late-onset sensorineural hearing loss in cCMV-infected neonates.

## Abstract

Congenital Cytomegalovirus (cCMV) infection is associated with numerous long-term sequelae. This scoping review consolidates existing evidence on fetal and neonatal immune response to cCMV and their potential relevance to clinical outcomes. A systematic search was conducted in the PubMed database. Observational studies were eligible when full text was available in English and data for immune response (innate, humoral, cellular) and/or immune-related biomarkers (cytokines and molecular markers) were provided. Thirty-four studies were included. CMV-infected fetuses mount robust γδ and CD8+ T-cell responses from the second trimester of pregnancy, with the transcriptomic and cytokine profile of their amniotic fluid revealing upregulation of IFN-γ-inducible genes and cytokines. cCMV-infected neonates mount oligoclonal γδ T-cell responses and functional NK and CD8+ T-cell responses, although data on the latter’s association with symptoms at birth are contradictory. Conversely, CD4+ T-cell responses are impaired, irrespective of symptoms. T cell exhaustion is an emerging finding with unclear implications on long-term outcome. Despite shared transcriptomic profiles between symptomatic and asymptomatic neonates, a 16-gene classifier biosignature has been identified for late-onset sensorineural hearing loss. In conclusion, immune response to cCMV is characterized by a Th1 signature, with T cell exhaustion being an emerging finding warranting further investigation.

## Linked entities

- **Genes:** IFNG (interferon gamma) [NCBI Gene 3458]
- **Diseases:** congenital Cytomegalovirus (MONDO:0017409), sensorineural hearing loss (MONDO:0010576)

## Full-text entities

- **Genes:** IFNA5 (interferon alpha 5) [NCBI Gene 3442] {aka IFN-alpha-5, IFN-alphaG, INA5, INFA5, leIF G}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, GNLY (granulysin) [NCBI Gene 10578] {aka D2S69E, LAG-2, LAG2, NKG5, TLA519}, MBL2 (mannose binding lectin 2) [NCBI Gene 4153] {aka COLEC1, HSMBPC, MBL, MBL2D, MBP, MBP-C}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, ADORA3 (adenosine A3 receptor) [NCBI Gene 140] {aka A3AR}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CCL22 (C-C motif chemokine ligand 22) [NCBI Gene 6367] {aka A-152E5.1, ABCD-1, DC/B-CK, MDC, SCYA22, STCP-1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, DEFB131A (defensin beta 131A) [NCBI Gene 644414] {aka DEFB-31, DEFB131}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, CCL8 (C-C motif chemokine ligand 8) [NCBI Gene 6355] {aka HC14, MCP-2, MCP2, SCYA10, SCYA8}, B3GAT1 (beta-1,3-glucuronyltransferase 1) [NCBI Gene 27087] {aka CD57, GLCATP, GLCUATP, HNK1, LEU7, NK-1}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, PF4 (platelet factor 4) [NCBI Gene 5196] {aka CXCL4, PF-4, SCYB4}, ST2 (suppression of tumorigenicity 2) [NCBI Gene 6761], CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, RGS18 (regulator of G protein signaling 18) [NCBI Gene 64407] {aka RGS13}, KAT7 (lysine acetyltransferase 7) [NCBI Gene 11143] {aka HBO1, HBOA, MYST2, ZC2HC7}, EOMES (eomesodermin) [NCBI Gene 8320] {aka TBR2}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, KLRC2 (killer cell lectin like receptor C2) [NCBI Gene 3822] {aka CD159c, NKG2-C, NKG2C}, IFNA21 (interferon alpha 21) [NCBI Gene 3452] {aka IFN-alphaI, LeIF F, leIF-F}, CXCL9 (C-X-C motif chemokine ligand 9) [NCBI Gene 4283] {aka CMK, Humig, MIG, SCYB9, crg-10}, RABGAP1 (RAB GTPase activating protein 1) [NCBI Gene 23637] {aka GAPCENA, TBC1D11}, ARHGEF9 (Cdc42 guanine nucleotide exchange factor 9) [NCBI Gene 23229] {aka COLLYBISTIN, DEE8, EIEE8, HPEM-2, PEM-2, PEM2}, LEO1 (LEO1 component of Paf1/RNA polymerase II complex) [NCBI Gene 123169] {aka RDL}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, IFNA13 (interferon alpha 13) [NCBI Gene 3447], ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, HLA-E (major histocompatibility complex, class I, E) [NCBI Gene 3133] {aka HLA-6.2, QA1}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, IFNA7 (interferon alpha 7) [NCBI Gene 3444] {aka IFN-alphaJ, IFNA-J}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, CYP39A1 (cytochrome P450 family 39 subfamily A member 1) [NCBI Gene 51302], CLEC4G (C-type lectin domain family 4 member G) [NCBI Gene 339390] {aka DTTR431, LP2698, LSECtin, UNQ431}, IFNA4 (interferon alpha 4) [NCBI Gene 3441] {aka IFN-alpha4a, INFA4}, IFNA8 (interferon alpha 8) [NCBI Gene 3445] {aka IFN-alphaB}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, IL25 (interleukin 25) [NCBI Gene 64806] {aka IL17E}, ARRB1 (arrestin beta 1) [NCBI Gene 408] {aka ARB1, ARR1}, GPR34 (G protein-coupled receptor 34) [NCBI Gene 2857] {aka LPS1, LYPSR1}, PRX (periaxin) [NCBI Gene 57716] {aka CMT4F}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, KLRC1 (killer cell lectin like receptor C1) [NCBI Gene 3821] {aka CD159A, NKG2, NKG2A}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, RNLS (renalase, FAD dependent amine oxidase) [NCBI Gene 55328] {aka C10orf59, RENALASE}, AK4 (adenylate kinase 4) [NCBI Gene 205] {aka AK 4, AK3, AK3L1, AK3L2}, CD7 (CD7 molecule) [NCBI Gene 924] {aka GP40, LEU-9, TP41, Tp40}
- **Diseases:** congenital (MESH:D008209), injury to (MESH:D014947), inflammation (MESH:D007249), hearing loss (MESH:D034381), SNHL (MESH:D006319), CMV infection (MESH:D003586), splenomegaly (MESH:D013163), microcephaly (MESH:D008831), thrombocytopenia (MESH:D013921), HCMV infection (MESH:D007239), chorioretinitis (MESH:D002825), Cytotoxicity (MESH:D064420), neuroimaging abnormalities (MESH:D000014), viral infections (MESH:D014777), brain abnormalities (MESH:D001927), cystic lesions (MESH:D052177), neurological damage (MESH:D020196), ADCC (MESH:D007153), developmental delay (MESH:D002658), Zika virus infections (MESH:D000071243), ventriculomegaly (MESH:D006849), sepsis (MESH:D018805), NDI (MESH:D009422), bacterial (MESH:D001424), prematurity (MESH:C536271), hepatitis (MESH:D056486)
- **Chemicals:** valacyclovir (MESH:D000077483), PMA (-), valganciclovir (MESH:D000077562), Ca+ (MESH:D002118), lipid (MESH:D008055)
- **Species:** Cowpea chlorotic mottle virus (no rank) [taxon 12303], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** AUC of 0, rs1024611

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945067/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945067/full.md

## References

93 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945067/full.md

---
Source: https://tomesphere.com/paper/PMC12945067